Skip to content

Study · Not a test of the peptide alone · 2009

6 results

A new immunomodulatory therapy for severe sepsis: Ulinastatin Plus Thymosin {alpha} 1.

Li Yumin, Chen Hao, Li Xun, Zhou Wence, He Minyan, Chiriva-Internati M, Wachtel MS, Frezza EE

Journal of intensive care medicine25 Nov 2008Cited by 31 (Europe PMC)

PMID19033321 (opens in a new tab)DOI10.1177/0885066608326970 (opens in a new tab)PepBankPUB-19033321
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone6

In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin alpha-1.

  1. 01HumanNot a test of Thymosin alpha-1 aloneRandomized controlled trialEfficacy outcome

    In sepsis patients, ulinastatin plus thymosin alpha‑1 gave 78% cumulative survival versus 60% with placebo.

    In plain wordsIn sepsis patients, ulinastatin plus thymosin alpha‑1 was linked to higher survival (78%) than placebo (60%).

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseCumulative survival
    Study

    n = 56

    Comparator
    Placebo
    Outcome group
    Mortality · Infection

    Measurements

    Cumulative survival
    78%
    treatment
    Cumulative survival
    60%
    placebo

    Source sentences

    Summary
    The treatment group experienced a 78% cumulative survival, the placebo group experienced a 60% cumulative survival; the survival difference was mirrored by Acute Physiology and Chronic Health Evaluation II scores and more quickly improved leukocyte counts, lymphocyte counts, coagulation parameters,…
    1 context sentence
    Summary · context
    A total of 56 sepsis patients were randomized into a treatment group, receiving immunomodulatory therapy, and a placebo group, a placebo.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  2. 02HumanNot a test of Thymosin alpha-1 aloneRandomized controlled trialEfficacy outcome

    In sepsis patients, the survival difference with ulinastatin plus thymosin alpha‑1 was mirrored by APACHE II scores.

    In plain wordsIn sepsis patients, APACHE II severity scores followed the survival difference between ulinastatin plus thymosin alpha‑1 and placebo.

    Peptide
    Thymosin alpha-1
    Outcome
    Direction not reportedAPACHE II scores
    Study

    n = 56

    Comparator
    Placebo
    Outcome group
    Intensive care and hospital outcomes · Infection

    Source sentences

    Summary
    The treatment group experienced a 78% cumulative survival, the placebo group experienced a 60% cumulative survival; the survival difference was mirrored by Acute Physiology and Chronic Health Evaluation II scores and more quickly improved leukocyte counts, lymphocyte counts, coagulation parameters,…
    1 context sentence
    Summary · context
    A total of 56 sepsis patients were randomized into a treatment group, receiving immunomodulatory therapy, and a placebo group, a placebo.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  3. 03HumanNot a test of Thymosin alpha-1 aloneRandomized controlled trialEfficacy outcome

    In sepsis patients, leukocyte counts improved more quickly with ulinastatin plus thymosin alpha‑1 than with placebo.

    In plain wordsIn sepsis patients, white blood cell counts improved faster with ulinastatin plus thymosin alpha‑1 than with placebo.

    Peptide
    Thymosin alpha-1
    Outcome
    Direction not reportedLeukocyte counts
    Study

    n = 56

    Comparator
    Placebo
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    The treatment group experienced a 78% cumulative survival, the placebo group experienced a 60% cumulative survival; the survival difference was mirrored by Acute Physiology and Chronic Health Evaluation II scores and more quickly improved leukocyte counts, lymphocyte counts, coagulation parameters,…
    1 context sentence
    Summary · context
    A total of 56 sepsis patients were randomized into a treatment group, receiving immunomodulatory therapy, and a placebo group, a placebo.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  4. 04HumanNot a test of Thymosin alpha-1 aloneRandomized controlled trialEfficacy outcome

    In sepsis patients, lymphocyte counts improved more quickly with ulinastatin plus thymosin alpha‑1 than with placebo.

    In plain wordsIn sepsis patients, lymphocyte counts improved faster with ulinastatin plus thymosin alpha‑1 than with placebo.

    Peptide
    Thymosin alpha-1
    Outcome
    Direction not reportedLymphocyte counts
    Study

    n = 56

    Comparator
    Placebo
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    The treatment group experienced a 78% cumulative survival, the placebo group experienced a 60% cumulative survival; the survival difference was mirrored by Acute Physiology and Chronic Health Evaluation II scores and more quickly improved leukocyte counts, lymphocyte counts, coagulation parameters,…
    1 context sentence
    Summary · context
    A total of 56 sepsis patients were randomized into a treatment group, receiving immunomodulatory therapy, and a placebo group, a placebo.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  5. 05HumanNot a test of Thymosin alpha-1 aloneRandomized controlled trialEfficacy outcome

    In sepsis patients, coagulation parameters improved more quickly with ulinastatin plus thymosin alpha‑1 than with placebo.

    In plain wordsIn sepsis patients, blood clotting measures improved faster with ulinastatin plus thymosin alpha‑1 than with placebo.

    Peptide
    Thymosin alpha-1
    Outcome
    Direction not reportedCoagulation parameters
    Study

    n = 56

    Comparator
    Placebo
    Outcome group
    Bleeding and clotting · Infection

    Source sentences

    Summary
    The treatment group experienced a 78% cumulative survival, the placebo group experienced a 60% cumulative survival; the survival difference was mirrored by Acute Physiology and Chronic Health Evaluation II scores and more quickly improved leukocyte counts, lymphocyte counts, coagulation parameters,…
    1 context sentence
    Summary · context
    A total of 56 sepsis patients were randomized into a treatment group, receiving immunomodulatory therapy, and a placebo group, a placebo.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  6. 06HumanNot a test of Thymosin alpha-1 aloneRandomized controlled trialEfficacy outcome

    In sepsis patients, cytokine levels improved more quickly with ulinastatin plus thymosin alpha‑1 than with placebo.

    In plain wordsIn sepsis patients, cytokine levels improved faster with ulinastatin plus thymosin alpha‑1 than with placebo.

    Peptide
    Thymosin alpha-1
    Outcome
    Direction not reportedCytokine levels
    Study

    n = 56

    Comparator
    Placebo
    Outcome group
    Inflammation markers · Immune and inflammation

    Source sentences

    Summary
    The treatment group experienced a 78% cumulative survival, the placebo group experienced a 60% cumulative survival; the survival difference was mirrored by Acute Physiology and Chronic Health Evaluation II scores and more quickly improved leukocyte counts, lymphocyte counts, coagulation parameters,…
    1 context sentence
    Summary · context
    A total of 56 sepsis patients were randomized into a treatment group, receiving immunomodulatory therapy, and a placebo group, a placebo.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.